Immunology

COVID-19

All eyes on ButanVac

New vaccine candidate uses a more stable version of the spike protein

By

COVID-19

Two vaccines prevent infection by Sars-CoV-2

Pfizer-BioNTech and Moderna vaccines are 80% effective at preventing SARS-Cov-2 infections after the first dose and 90% after the second

By

COVID-19

Superior immunity

Studies of blood and tissue samples taken before the COVID-19 pandemic may help explain why the disease is more common and more severe in adults than in children

By

photolab

Lethal networks

Faced with an invasion of viruses or bacteria, human immune system cells sometimes overreact in a process known as NETosis, which has been shown to be more severe when the invader is SARS-CoV-2

By

COVID-19

New vaccines on the way

Butantan Institute and federal government plan to start human trials of two vaccine candidates in the coming months

By and

INTERVIEW

Eurico Arruda: Admirer of viruses

Coronavirus specialist and USP physician speaks about the new variants of SARS-CoV-2 and the risk they represent in the efficacy of some vaccines

By

Covid-19

The expected effect of vaccines

Administering vaccines on a large scaled will tell us whether, in addition to protecting against the disease, they are also able to prevent infection by SARS-CoV-2

By

Covid-19

Obstacle course

Research centers working on vaccines for the novel coronavirus in Brazil face major hurdles

By

Covid-19

Antibodies reduce deaths

A clinical trial led by researchers at the University of Oxford, UK, identified a second drug capable of reducing mortality among patients with severe COVID-19

By

Public health

Vaccinations have prevented 37 million deaths in 98 countries

Immunization against major diseases has had a significant impact on public health in low- and middle-income countries, helping to save 37 million lives between 2000 and 2019

By

INTERVIEW

Dimas Covas: The trajectory of Butantan

The hematologist from USP readies the São Paulo institute to fight the pandemic and has plans to transform it into one of the world’s top producers of vaccines and serums

By and

COVID-19

vaccine. Now what?

The introduction of vaccines in the battle against the COVID-19 pandemic raises new challenges

By

COVID-19

A more balanced game

Approved for emergency use, CoronaVac is the first vaccine to be offered in Brazil

By

COVID-19

Yes to the vaccine

On January 18, FAPESP started the #vacinasim (“yesvaccine”) social media campaign to reinforce public confidence in their safety and effectiveness

By

COVID-19

Immunity could be long-lasting

The immune system's ability to recognize the novel coronavirus and fight it seems to last for at least eight months

By

COVID-19

The era of genetic vaccines

The vaccines from BioNTech/Pfizer and Moderna result from historical investments in messenger RNA technology leading to the creation of new products

By

COVID-19

Distribution challenges

Governments need to work with pharmaceutical and logistics companies to overcome obstacles to start the SARS-CoV-2 immunization campaign

By

COVID-19

Approval strategy

Amid uncertainty, São Paulo announces state vaccination plan

By

COVID-19

Butantan develops serum for the novel coronavirus

The Butantan Institute has completed development of a serum to combat SARS-CoV-2

By

COVID-19

Unequal access

Even before efficacy data for the vaccine candidates was released, it was clear that there will not be enough supply to immunize the entire global population before the end of next year

By

COVID-19

Australia gives up on vaccine candidate

A vaccine being developed by the University of Queensland and biotechnology company CSL, both from Australia, is the first of more than 200 candidates to be discarded

By

COVID-19

Vaccines and sharks

A compound extracted from the livers of sharks is used in five coronavirus vaccine candidates

By

Cover

Vaccines edge closer

Less than a year after first cases of COVID-19 were confirmed, vaccine candidates in the final stages of development offer promising results

By

COVID-19

Nasal spray prevents infection in ferrets

A nasal spray tested on ferrets prevented absorption of SARS-CoV-2 and for a period of 24 hours, prevented them from becoming infected with the novel coronavirus when exposed to animals known to be affected by the pathogen

By

COVID-19

Preexisting antibodies against SARS-CoV-2

Antibodies against other varieties of coronavirus are in some cases capable of recognizing SARS-CoV-2 and providing some degree of protection to those who have not yet contracted the COVID-19 pathogen

By

COVID-19

Stuttering progress

Advanced testing of COVID-19 vaccines continues at an accelerated pace, despite occasional interruptions caused by safety concerns

By

COVID-19

The fatality conundrum

Difficulties identifying the exact number of people infected and killed make it hard to calculate how deadly the disease is

By

COVID-19

Science under pressure

Political interference in the approval process may undermine public confidence in vaccine development, researchers warn

By

COVID-19

Study determines Chinese vaccine is safe

CoronaVac is safe and has no serious side effects

By

Video

Why the Covid-19 vaccine is important

Never before so many vaccines have been developed at the same time against a single disease, nor so rapidly | 7'32

By